Introduction: the coming of age of RNAi screening technology
============================================================

The landmark discovery of RNA interference (RNAi) as a mechanism for gene regulation in eukaryotic cells was a defining scientific achievement of the past two decades. Equally impressive was the technologisation of RNAi that rapidly followed, which has revolutionised the research process for the biological sciences. Reverse genetic experiments using RNAi tools are extremely informative and usually incisive, as well as inexpensive, quick, and easy to perform. Advances in delivery vectors have enabled RNAi experiments in almost all cell types, both *in vitro* and increasingly *in vivo*. Importantly, the acquisition, annotation, and accessibility of the complete genome sequences for humans and commonly used model organisms has greatly expanded the utility of RNAi reagents. Not only has this genomic information vastly broadened the usability of RNAi technology in reductionist-type experiments, but also it has allowed for the adaptation of RNAi tools for large-scale forward genetic screens.

Nearing a decade old and ever evolving, genome-wide RNAi technology has certainly come of age. The fruit borne from recent screens are plentiful as follows: novel mechanisms elucidated in signal transduction pathways, such as those involved in the DNA damage response ([@bib6]), integrin ([@bib24]), and NF-*κ*B ([@bib19]) signalling; new insights into fundamental biological processes, such as antigen presentation ([@bib21]), autophagy ([@bib20]), and pluripotency ([@bib5]); identification of therapeutic targets for pathological processes, such as tumourigenesis ([@bib13]), tumour maintenance ([@bib34]), and resistance to cancer treatment ([@bib10]); and the annotation of hundreds of biological contact points between host organisms and pathogenic viruses (reviewed in [@bib9]). As a particularly illustrative example, [@bib13] recently published tantalising data from a genome-wide RNAi screen probing human mammary epithelial cells for 'non-oncogenic support pathways\' for the *Myc* oncogene ([@bib13]). Dysregulated in ∼25% of breast cancers, Myc is required for tumour maintenance and progression, and is associated with very poor prognosis; however, despite intensive efforts spanning nearly three decades there is no effective way to target Myc in human cancers. Taking a synthetic lethal RNAi screening approach, [@bib13] identified a SUMOylation-dependent transcriptional programme that is essential for Myc-induced tumourigenesis. In Myc-driven cancers, the authors showed that SUMO-activating enzyme 2 (SAE2) is required to maintain a supportive Myc transcriptional subprogramme in its activated state. Loss of SAE2 represses this programme and leads to mitotic collapse and cell death in tumours with hyperactivated Myc.

In the realm of cancer research, the work by [@bib13] highlights one of the great strengths of genome-scale RNAi screening: the ability to identify tumour vulnerabilities that are not oncogenic *per se*. Similar genome-scale synthetic lethal studies have been conducted with the frequently hyperactivated and difficult-to-target oncogene *RAS*, generating equally impressive results ([@bib26]). These studies illuminate a growing trend in cancer research: discovering and targeting non-oncogene addiction (NOA) in tumours ([@bib14]). Since the discovery of the *Src* oncogene over four decades ago, small and large-scale sequencing efforts have been aimed towards identifying oncogenes in human cancers. As a collective, this pursuit has generated an unprecedented wealth of information. Hundreds of oncogenes have been catalogued and a staggering amount has been learned about the genesis and maintenance of human tumours. Unfortunately for cancer patients, this work has also taught us that oncogenes are not, generally speaking, useful therapeutic targets ([@bib22]). This great effort informed us that, with a few notable exceptions such as chronic myelogenous leukaemia, cancer is a disease of genetic and phenotypic heterogeneity, consisting of distinct cell populations that are maintained by a distinct set of oncogenic mutations ([@bib28]). A drug that inhibits an individual oncogene, therefore, only targets a subset of the cancer\'s cells; in fact, as the cancer ecosystem is one where tumour cells are forever competing for resources, removing a sub-population of cancer cells can inadvertently facilitate the expansion of another, perhaps more resistant sub-population, a concept known as competitive release ([@bib11]). These research pursuits also taught us that cancer genomes are highly unstable and cellular signalling pathways are functionally degenerate. Consequently, the selective pressures applied by drugs targeting a single oncogene within a particular growth pathway invariably leads to adaptive tumour evolution and drug resistance ([@bib32]).

Fortunately, on the heels of these sobering realities a new paradigm has emerged that oncogenes themselves are dependent upon normal cellular signalling networks, and that cancer cells are dependent upon normal cellular stress responses ([@bib29]). These NOAs are not genetically mutated and, thus, would not be detected in an audit of a cancer\'s genome. They are, however, disproportionately critical to the viability of tumour as compared with normal cells. Emboldened by the prospect that these non-oncogenic support pathways may be common to multiple oncogenes, have fewer functional redundancies with which to permit a path for resistance, and offer multiple drug targets, many cancer scientists have begun to herald the pursuit of non-oncogene targets as the new path forward ([@bib14]). By its very nature, genome-scale RNAi screening technology is tailor-made to discovering these critical supportive vulnerabilities in tumours.

RNAi screening to enhance oncolytic virus therapy for cancer
============================================================

High-throughput RNAi screening is also, as it turns out, tailor-made to functionally annotate interactomes between host organisms and pathogenic viruses (reviewed in [@bib9]). Somewhat analogous to the cancer story, an emerging movement in the infectious disease field has been to target host factors required for a productive virus infection. This therapeutic approach was borne out of realisation that virus factors, although conceptually attractive targets because they should, in theory, provide a wide therapeutic index, are challenging points of intervention because of the high mutability of their genomes. This is particularly true for RNA viruses, such as HIV, which requires a cocktail of drugs inhibiting multiple virus proteins for effective management. Targeting key host factors, on the other hand, may be a more tractable approach, as it should be more difficult for a virus to develop resistance. A major step forward for this idea occurred in 2007, when the FDA approved the chemokine (C--C motif) receptor 5 inhibitor, maraviroc, as the first-in-class drug targeting a host factor required for a pathogenic virus (HIV-1, R5 strain; [@bib25]).

Given the extraordinary power of genome-scale RNAi screening for discovering cancer vulnerabilities and host factors for viral pathogens, and the attractiveness of targeting host factors to alter virus productivity, we have argued that a synthetic lethal RNAi screen in resistent cancer cells with a cancer-fighting OV should uncover unforeseen and therapeutically relevant biological nexuses between the host\'s tumour and the OV ([@bib16]). Also undergoing a coming of age, OV therapy uses non-pathogenic or attenuated viruses that have natural or engineered tropism for tumour cells to treat cancer (reviewed in [@bib1]). Three features make OVs particularly attractive cancer therapeutics. The first is that they seek out tumour cells based on downstream consequences of an oncogenic mutation, that is, altered molecular circuitry and/or NOA, such as attenuated type I interferon signalling, rather than targeting an oncogene *per se* ([@bib30]). The second is that they lead to cancer cell killing through multiple mechanisms of action, such as directly lysing tumour cells ([@bib31]), stimulating anti-tumour immunity ([@bib7]), and starving a cancer by infecting endothelial cells and inducing tumour vasculature collapse ([@bib2]). The third is that they are programmable machines, that is, they can be genetically engineered in creative ways to enhance efficacy, such as arming them with the anti-tumour immune cytokine GM-CSF ([@bib3]). Collectively, these three features may help counter the evasive nature of malignancy that currently stymies existing cancer therapies. And with three OV platforms currently in phase II/b or III clinical evaluation for multiple cancer indications, it appears that oncolytic virus therapy (OVT) is poised to become an approved treatment option within the next 2--5 years (reviewed in [@bib1]).

We recently published the first report of a genome-wide RNAi screen specifically designed to probe the interactome between cancer cells and an OV ([@bib15]). Using the oncolytic rhabdovirus *Maraba* ([@bib4]), we performed cell-based synthetic lethal analyses with three distinct cancer genomes, from which an intriguing concept unfolded; inducing a mild, transient stress by inhibiting a non-oncogene support pathway can lead to tumour-specific reprogramming that renders cancer cells susceptible to a partnered therapeutic agent. Specifically, we found that transiently blocking components of the ER stress response, a common NOA in many tumours, leads to a gradual accumulation of misfolded proteins in the ER. During the stress-management process that ensues, levels of the adaptor protein RAIDD (RIP associated Ich-1/CED homologous protein with death domain) rise, which opens the door for caspase-2-mediated apoptosis when subsequently challenged with the oncolytic *Maraba* virus ([Figure 1](#fig1){ref-type="fig"}). In terms of clinical implications, it is noteworthy that ER stress response inhibitors and *Maraba* virus are both currently in preclinical development. Moreover, we found that the clinically approved cytotoxic agent doxorubicin, known to rely on the caspase-2/RAIDD signalling axis to induce cancer cell death, is also synergised by pretreatment with ER stress response inhibitors.

One feature of this study particularly stands out; the therapeutic index that we uncovered was a product of targeting a NOA. This was not by design, but rather an inadvertent byproduct of the RNAi screening approach taken. On the basis of the rich host--pathogen interactome data that were being generated for other viruses in similarly executed RNAi screens, we had anticipated discovering novel host factors that repress virus productivity, which could thereafter be targeted for a therapeutic gain. Instead, we discovered that inhibiting a non-oncogene support pathway synergised with OV-mediated killing in an unusual way. In contrast to studies like those published by [@bib13], which identified NOA as a stand-alone cancer vulnerability, our work revealed that targeting the NOA to the ER stress response induces adaptive rewiring in cancer cells that renders them highly susceptible to OV-mediated killing. In essence, our study demonstrated the capacity to engineer a cancer vulnerability by targeting a NOA, which can subsequently be exploited by a partnered OV ([@bib15]).

Recent advances in genome-scale RNAi screening technology
=========================================================

A number of technical innovations made over the past year are poised to improve genome-scale RNAi screening in three important ways. First, the development of next-generation inducible shRNA vectors and advances in mouse shRNA transgenic technology will make *in vivo* validation easier and more clinically relevant. Second, these new vector systems, coupled with recent advances in barcode deconvolution and bioinformatics, will enhance the utility of pooled shRNA screening *in vivo*. Third, the development of a massively parallel sensor assay for unbiased, high-throughput, functional evaluation of shRNA sequences is a prelude to the production of next-generation genome-wide shRNA resources that will be more potent and less noisy than the existing libraries.

NextGen shRNA vectors: implications for *in vivo* validation and pooled screening
---------------------------------------------------------------------------------

Third-generation inducible shRNA vectors have recently been developed ([@bib18]; [@bib33]). These expression vehicles, termed the TRMPV and pINDUCER series of vectors, offer one significant advantage over the first- and second-generation platforms, such as pSuperior.retro, Tet-pLKO-Puro, pLKO-puro-IPTG-1xLacO, pPRIME, pSLIK, and pTRIPZ ([@bib12]). Both TRMPV and pINDUCER vectors are modular systems that have the following features: mir30-based shRNA sequences and a fluorescent reporter under the control of the tetracycline response element; the reverse tetracycline transactivator and either a fluorescent or luminescent reporter, or a selectable gene marker under the control of constitutively active promoters; the choice of a retrovirus- or lentivirus-based delivery system; and compatibility with the existing Hannon--Ellidge miR30-based shRNA libraries. Collectively, these features bestow the ability to (1) induce potent and reversible silencing of any human or mouse gene upon the onset of disease; (2) conduct experiments with mixed cell populations, drug-selected populations, or highly expressing cell clones; (3) silence genes in nearly any primary or immortalised cell of interest; and (4) simultaneously track tumour size and shRNA expression *in vivo* with dual fluorescent and luminescent reporters.

Regarding *in vivo* validation, these next-generation vector systems endow the capacity to rapidly evaluate a cancer gene target in nearly any xenograft or syngeneic transplantable tumour model. The major advantage over previous technologies is that following transduction with a single TRMPV or pINDUCER vector, cancer cells can be monitored *in vivo* post-transplantation and gene silencing can be induced and monitored after the onset of detectable disease. In this scenario, target validation more closely resembles the human clinical situation.

Of course, silencing a gene target in cancer established on a wild-type background has one obvious limitation: therapeutic index cannot be evaluated. Ideally, transduced cells would be transplanted into recipient mice that themselves have the gene target under the control of the same inducible promoter. This approach would more closely mimic the clinical situation where both the cancer and the host are dosed with a therapeutic agent. The International Knockout Mouse Consortium is diligently working towards generating a conditional knockout mouse anthology that spans the entire genome; however, until the inducible models come on line, new developments in transgenic RNAi mouse technology offer an exciting alternative. Using modified retroviral-based shRNA vectors, two studies have recently demonstrated the feasibility of engineering transgenic shRNA mice that possess inducible, reversible, trackable, and high-level expression of RNAi *in vivo* ([@bib17]; [@bib23]). To be fair, these are not the first reports of inducible RNAi transgenic mice; however, their approach was developed to overcome the major limitation of the previous technology, that is, highly variable gene knockdown. By coupling a modified TMP shRNA vector to a Flp/FRT recombinase-mediated cassette exchange approach, the authors were able to reproducibly engineer single-copy, doxycycline-inducible RNAi transgenic embryonic stem cells with which to generate transgenic RNAi mice that had robust and reversible gene knockdown *in vivo*. With this advance, it is now theoretically possible to partner inducible gene knockdown in cancer cells with that in a recipient transgenic mouse, to fully recapitulate, genetically, the interactions between a drug, the cancer, and the host.

The ability of next-generation shRNA vectors to induce gene knockdown in transplantable cancer cells after the onset of disease in the recipient host is also an advantageous feature for *in vivo* pooled RNAi screening. Similar to its benefits for *in vivo* validation, silencing gene expression after disease onset is more likely to identify clinically useful cancer targets in an *in vivo* screen than an approach that uses stable gene silencing. To demonstrate proof-of-concept for using next-generation shRNA libraries for *in vivo* screening, [@bib33] spiked a library of 820 TRMPV shRNA vectors with three potent shRNAs targeting the replication protein A (*Rpa3*), a gene whose knockdown causes cell cycle arrest in dividing cells ([@bib33]). This pool was transduced into acute myeloid leukaemia (AML) cells, drug selected, and transplanted into recipient mice. After the onset of leukaemia, mice were left untreated or treated with doxycycline. After 10 days, AML cells were collected, sorted for Venus+dsRed+ expression (i.e., cells that were transduced and expressing their shRNA), and identified by deep sequencing. When compared with AML cells extracted from control mice, those derived from doxycycline-treated animals showed a 4- to 10-fold depletion of TRMPV--Rpa3. Furthermore, all three Rpa3 shRNAs spiked into the library were among the top 25 hits from the screen. Taken together, these data highlight the added benefits of next-generation inducible shRNA vectors that, when coupled with several recent innovations in barcode deconvolution and bioinformatics (e.g., [@bib27]), greatly improve the utility of pooled RNAi screens *in vivo* for the discovery of clinically relevant cancer gene targets.

RNAi design using a massively parallel sensor assay
---------------------------------------------------

As the requirements for efficient RNAi-mediated target suppression are not well known, shRNAs designed using the existing algorithms do not consistently knock down their target genes. To get around this knowledge gap, [@bib8] recently developed an innovative, unbiased high-throughput 'sensor\' assay to identify potent RNAi sequence on a large scale ([@bib8]). This technology consists of a single vector (pSENSOR) reporter assay containing doxycycline-inducible miR30-based shRNA sequences and a constitutively active Venus reporter coupled to the cognate RNAi target sequence (i.e., the 'sensor\'). The potency of a given shRNA sequence is evaluated by transducing cells with pSENSOR, dosing them with doxycycline, and monitoring the loss of Venus signal intensity (which will be degraded along with the sensor sequence). The major innovation here, when compared with other systems that similarly monitor RNAi potency, is that all the components are engineered into a single construct. This has two important implications as follows. (1) It allows the assay to be multiplexed. Similar to pooled RNAi screens, cells can be transduced at low multiplicity of infection to ensure a single integration per cell. Thousands of cells containing thousands of different shRNA sequences can then be combined, treated with doxycycline, and sorted by Venus intensity using FACS. Deep sequencing can subsequently identify the RNAi sequences that were particularly good at depleting the Venus signal strength. (2) Evaluating single-copy shRNA potency is highly relevant to the recent innovations in validation and pooled screening *in vivo* described above, which rely on potent single-copy gene silencing.

To test their system in high-throughput, [@bib8] multiplexed nearly 20 000 different shRNAs comprising every possible RNAi target sequence against 9 different genes. Following several rounds for FACS sorting of Venus-depleted cells, DNA sequencing confirmed the enrichment of 17 shRNA sequences that were previously known to potently induce gene silencing. Moreover, structure--function analyses of the 20 000 sequences revealed several previously unknown properties that affect shRNA efficacy, which have subsequently been incorporated into a new algorithm for shRNA design.

Conclusions: the future of RNAi screening to enhance OVT
========================================================

With a single published report of a functional genomic screen to identify cancer-specific targets for improving OVT ([@bib15]), and several important innovations in the shRNA field within the past 12 months, the future of RNAi screening to enhance OVT is extremely bright. We have previously outlined the points of intervention for OVT that can be studied using RNAi screening technology in cell-based experiments ([@bib16]). Forthcoming next-generation libraries containing more potent and specific shRNAs will make these screens more sensitive and accurate at identifying these therapeutic opportunities. Moreover, next-generation shRNA vectors will facilitate the rapid and clinically relevant evaluation of the screening hits in animal models, as well as the identification of new targets in a broader array of clinically significant *in vivo* screens. As a case in point, these novel platform will enhance our capacity to identify, using *in vivo* RNAi screens, points of intervention that cannot be discovered in cell-based assays, such as modulators of the tumour microenvironment, tumour immunity, and bystander killing. Together, these innovations are poised to streamline the process of discovery and preclinical validation of targets that, when inhibited, synergise with OVT ([Figure 2](#fig2){ref-type="fig"}). As the clinical approval of the first-in-class OVT may be just around the corner, the time is ripe to leverage these genome-scale RNAi tools to enhance OVT.

![Targeting a tumour-specific NOA to the ER stress response induces cancer cell rewiring and sensitisation to caspase-2- and RAIDD-dependent viral oncolysis. A genome-scale RNAi screen uncovered that targeting a tumour-specific NOA to the ER stress response causes a mild ER stress that evokes a corrective UPR in tumour cells. As a consequence, levels of the adaptor protein RAIDD increase, which sensitises tumour cells to caspase-2-dependent apoptosis when challenged with a partnered therapeutic oncolytic virus. NOA, non-oncogene addiction; ER, endoplasmic reticulum; UPR, unfolded protein response.](bjc2012467f1){#fig1}

![Pipeline for genome-wide RNAi screening to enhance OVT. Using genome-scale siRNA and shRNA libraries, both cell-based and *in vivo* screens can be used to catalogue the genes involved in many aspects of the tumour--OV--host interactomes. Following hit deconvolution and bioinformatic analyses, clinically relevant secondary *in vivo* validation can be performed using novel inducible RNAi reagents in xenografts or syngeneic transplantable tumour models on a matching inducible RNAi transgenic mouse. OVT, oncolytic virus therapy.](bjc2012467f2){#fig2}
